Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Innate Pharma (NASDAQ:IPHA), Zentalis Pharma (NASDAQ:ZNTL), Fate Therapeutics (NASDAQ:FATE), Kyverna Therapeutics (NASDAQ:KYTX) and TScan Therapeutics (NASDAQ:TCRX).
Adaptimmune Therapeutics has a consensus price target of $3.86.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $0.59 last updated January 24, 2025 at 6:14 PM EST.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q4 earnings are confirmed for Wednesday, March 5, 2025.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.